BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 1,484 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,484 shares of BeOne Medicines stock in a transaction on Monday, June 8th. The stock was sold at an average price of $269.37, for a total transaction of $399,745.08. Following the sale, the chief operating officer owned 40 shares of the company’s stock, valued at $10,774.80. The trade was a 97.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 1.7%

NASDAQ:ONC opened at $263.61 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $239.25 and a 12 month high of $385.22. The firm has a fifty day simple moving average of $301.03 and a 200-day simple moving average of $315.60. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $28.92 billion, a P/E ratio of 58.97 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion during the quarter. On average, equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds have recently modified their holdings of ONC. EFG International AG purchased a new stake in shares of BeOne Medicines during the 4th quarter worth about $25,000. Leonteq Securities AG purchased a new stake in shares of BeOne Medicines during the 4th quarter worth about $35,000. Daiwa Securities Group Inc. purchased a new stake in shares of BeOne Medicines during the 2nd quarter worth about $35,000. CWM LLC boosted its stake in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the 4th quarter worth about $61,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ONC has been the subject of several recent research reports. Leerink Partners raised their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Wolfe Research initiated coverage on shares of BeOne Medicines in a report on Friday, March 27th. They set an “outperform” rating and a $340.00 target price for the company. Truist Financial reissued a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 4th. Finally, Barclays raised their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BeOne Medicines currently has an average rating of “Moderate Buy” and an average target price of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.